Klotho vs SNAP-8 (Acetyl Octapeptide-3)
A neutral, side-by-side comparison of two anti-aging & longevity peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Klotho
Anti-aging protein discovered in 1997 whose deficiency causes a syndrome resembling accelerated aging across multiple organ systems. Circulating soluble klotho declines ~40% from age 40–80. Research into klotho-derived peptides and recombinant protein explores neuroprotection, cardiac protection, renal anti-fibrosis, and metabolic anti-aging benefits. The KL-VS polymorphism provides a natural human model of elevated klotho activity.
Full profileSNAP-8 (Acetyl Octapeptide-3)
8-amino acid cosmetic peptide active (Acetyl Octapeptide-3) that competes with SNARE complex proteins to reduce neuromuscular signal transmission in facial expression muscles. An extended, more potent version of Argireline (Acetyl Hexapeptide-3). Clinical studies show 26–63% reduction in expression wrinkle depth with twice-daily application, positioning it as a topical botulinum toxin alternative.
Full profile| Klotho | SNAP-8 (Acetyl Octapeptide-3) | |
|---|---|---|
| Category | Anti-Aging & Longevity | Anti-Aging & Longevity |
| Also known as | α-Klotho, soluble Klotho, KL-VS, klotho protein, KL1 domain | Leuphasyl, Acetyl Octapeptide-3, SNAP-8 peptide, Argireline extension, Acetyl Glutamyl Heptapeptide-3 |
| Evidence | Research-stage | Research-stage |
| Dosing range | 1mcg/kg–10mcg/kg mcg/kg, every 3–7 days IV or SC (research) | 1%–10% %, twice daily topical application |
| Administration | Intravenous (research), Subcutaneous injection | Topical (serum/cream) |
| Key side effects | Hypophosphatemia (klotho inhibits FGF23 signaling → phosphate wasting), Hypocalcemia (secondary to phosphate effects), Altered vitamin D metabolism, Potential for altered mineral homeostasis with chronic administration | Very well-tolerated, Rare mild skin irritation or redness, No systemic absorption at cosmetic concentrations, No paralysis risk (partial SNARE competition only) |
| Cited sources | 2 references | 2 references |
Key differences
- Administration: Klotho — Intravenous (research), Subcutaneous injection; SNAP-8 (Acetyl Octapeptide-3) — Topical (serum/cream).
- Dosing units differ: Klotho is dosed in mcg/kg, SNAP-8 (Acetyl Octapeptide-3) in % — they operate at different scales.
- Frequency: Klotho is typically every 3–7 days IV or SC (research); SNAP-8 (Acetyl Octapeptide-3) is twice daily topical application.
How each works
Klotho
α-Klotho functions as both a transmembrane co-receptor for FGF23 (regulating phosphate and vitamin D) and as a shed soluble circulating factor with FGF23-independent longevity effects. Soluble klotho activates longevity-associated pathways: Nrf2/antioxidant defense, FOXO transcription factors, and Wnt/TGF-β inhibition for anti-fibrotic effects. The klotho-deficient mouse ages rapidly and dies young; klotho-overexpressing mice live 20–30% longer.
SNAP-8 (Acetyl Octapeptide-3)
SNAP-8 mimics the N-terminal domain of SNAP-25, competing for SNARE complex assembly required for acetylcholine vesicle fusion at the neuromuscular junction. This partial inhibition reduces muscle contraction intensity without complete paralysis. Clinical studies demonstrate statistically significant reductions in crow's feet and forehead line depth after 28 days of use at 5–10% concentration.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.